| Literature DB >> 34959946 |
Jun Watanabe1,2, Atsushi Miki1, Masaru Koizumi1, Kazuhiko Kotani2, Naohiro Sata1.
Abstract
BACKGROUND: Previous systematic reviews have not clarified the effect of postoperative coffee consumption on the incidence of postoperative ileus (POI) and the length of hospital stay (LOS). We aimed to assess its effect on these postoperative outcomes.Entities:
Keywords: abdominal surgery; caffeine; coffee; ileus; length of stay; meta-analysis; systematic review
Mesh:
Substances:
Year: 2021 PMID: 34959946 PMCID: PMC8708428 DOI: 10.3390/nu13124394
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow of the study search process.
The characteristics of the included studies.
| Authors | Year | Country | No. | Age, Year | Male, % | Surgical | Coffee | Volume, mL | Frequency | Control |
|---|---|---|---|---|---|---|---|---|---|---|
| Müller [ | 2012 | Germany | 79 | 61 | 56 | CRS | Caffeine | 100 | TDS | Water |
| Dulskas [ | 2015 | Lithuania | 90 | 65 | 53 | CRS | Caffeine, Decaf | 100 | TDS | Water |
| Piric [ | 2015 | Bosnia and | 58 | 63 | 59 | CRS | Caffeine | 100 | TDS | Tea |
| Göymen [ | 2016 | Turkey | 75 | 50 | 0 | CS | Decaf | 100 | TDS | Water, no intervention |
| Güngördük [ | 2017 | Turkey | 114 | 55 | 0 | GS | Caffeine | 100 | TDS | No intervention |
| Mohamed [ | 2018 | Egypt | 210 | NR | 0 | CS | NR | NR | NR | No intervention |
| Rabiepoor [ | 2018 | Iran | 100 | 28 | 0 | CS | Caffeine | 100 | TDS | Water |
| Hasler-Gehrer [ | 2019 | Switzerland | 115 | 66 | 51 | CRS | Caffeine | 150 | TDS | Tea |
| Hayashi [ | 2019 | Japan | 46 | 77 | 26 | CRS | Caffeine | 100 | TDS | Water |
| Bozkurt Koseoglu [ | 2020 | Turkey | 113 | 29 | 0 | CS | Caffeine | 100 | TDS | No intervention |
| Güngördük [ | 2020 | Turkey | 96 | 60 | 0 | GS | Caffeine | 150 | TDS | Water |
| Kanza Gül [ | 2021 | Turkey | 80 | 28 | 0 | CS | Decaf | NR | TDS | No intervention |
| Parnasa [ | 2021 | Israel | 70 | 56 | 50 | CRS | Caffeine | 50 * | TDS | Placebo |
CRS, colorectal surgery; CS, caesarean section; GS, gynecological surgery; No., number; NR, not reported; TDS, three times per day. * 100 mg of caffeine citrate.
Risk of bias for the eligibility studies for the time to first defecation.
| Authors | Risk of Bias 2 Tool Assessment | |||||
|---|---|---|---|---|---|---|
| Bias Arising from the Randomization Process | Bias Due to Deviations from Intended Interventions | Bias Due to Missing Outcome Data | Bias in the Measurement of the Outcome | Bias in the Selection of the Reported Results | Overall Risk of Bias | |
| Müller [ | Low | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Dulskas [ | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Piric [ | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Göymen [ | Some concerns | Low | Low | Some concerns | Some concerns | Some concerns |
| Güngördük [ | Some concerns | Low | Low | Some concerns | High | High |
| Mohamed [ | Some concerns | High | High | Some concerns | Some concerns | High |
| Rabiepoor [ | Some concerns | Low | Low | Some concerns | Some concerns | Some concerns |
| Hasler-Gehrer [ | Low | Some concerns | Some concerns | Some concerns | Low | Some concerns |
| Hayashi [ | Low | Low | Low | Some concerns | Low | Some concerns |
| Bozkurt Koseoglu [ | Low | Some concerns | Some concerns | Some concerns | Low | Some concerns |
| Güngördük [ | Low | Some concerns | Some concerns | Some concerns | Low | Some concerns |
| Kanza Gül [ | Low | Low | Low | Some concerns | Some concerns | Some concerns |
| Parnasa [ | Low | Some concerns | Some concerns | Some concerns | Low | Some concerns |
Summary of findings.
| Effect of Postoperative Coffee Consumption after Abdominal Surgery | ||||||
|---|---|---|---|---|---|---|
| Patient: Adults after Abdominal Surgery; Setting: In-Patients; Intervention: Coffee; Comparison: Control | ||||||
| Outcomes | Anticipated Absolute Effects * (95% CI) | Relative Effect | Patient Number (Studies) | Certainty of the Evidence | Comments | |
| Risk with control | Risk with coffee | |||||
| Time to first defecation | The median time was 42 h. | MD −10 h | - | 1209 | Moderate a | Coffee reduced the time to first defecation. |
| Length of hospital stay | The median stay was 6 days. | MD −1.5 days | - | 905 | Low a,b | Coffee reduced the length of hospital stay. |
| Postoperative ileus | 165 per 1000. | 69 per 1000 | RR 0.42 | 913 | Low a,b | Coffee reduced postoperative ileus. |
| Time to first flatus | The median time was 30 h. | MD −4.3 h | - | 1113 | Low a,b | Coffee reduced the time to first flatus. |
| Time to first bowel sound | The median time was 10 h. | MD −4.3 h | - | 683 | Very low a,b,c | Coffee reduced the time to first bowel sound. |
| Time to tolerance of solid food | The median time was 48 h. | MD −9.9 h | - | 833 | Low a,b | Coffee reduced the time to first tolerance of solid food. |
CI, confidence interval; MD, mean difference; RR, risk ratio. * The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). GRADE Working Group grades of evidence; High certainty: We are very confident that the true effect lies close to that of the estimated effect. Moderate certainty: We are moderately confident in the estimated effect. The true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the estimated effect is limited: The true effect may be substantially different from the estimated effect. Very low certainty: We have very little confidence in the estimated effect. The true effect is likely to be substantially different from the estimated effect. a Downgraded because of a high risk of bias. b Downgraded because of inconsistency due to substantial heterogeneity. c Downgraded because of imprecision due to the small sample size.
Figure 2Forest plot of the time to first defecation.
Figure 3Forest plot of the length of hospital stay.
Figure 4Forest plot of postoperative ileus.
Figure A1Forest plot of the time to first flatus.
Figure A2Forest plot of the time to first bowel sound.
Figure A3Forest plot of the time to toleration of solid food.
Figure A4Forest plot of complications/adverse events.
Figure A5Forest plot of time to first defecation by coffee types (caffeinated or decaffeinated coffee).
Figure A6Forest plot of length of hospital stay by coffee types (caffeinated or decaffeinated coffee).
Figure A7Forest plot of postoperative ileus by coffee types (caffeinated or decaffeinated coffee).
Figure A8Forest plot of time to first flatus by coffee types (caffeinated or decaffeinated coffee).
Figure A9Forest plot of time to first bowel sound by coffee types (caffeinated or decaffeinated coffee).
Figure A10Forest plot of time to toleration of solid food by coffee types (caffeinated or decaffeinated coffee).
Figure A11Forest plot of complications/adverse events by coffee types (caffeinated or decaffeinated coffee).
Figure A12Forest plot of time to first defecation by coffee types (caffeinated or decaffeinated coffee) in (A) colorectal surgery and (B) cesarean section.
Figure A13Forest plot of time to toleration of solid food by coffee types (caffeinated or decaffeinated coffee) in cesarean section.
Figure A14Forest plot of length of hospital stay excluding studies using imputed statistics.
Figure A15Forest plot of time to first flatus excluding studies using imputed statistics.
Figure A16Forest plot of time to toleration of solid food excluding studies using imputed statistics.
Figure A17The funnel plot.
PRISMA 2020 Checklist.
| Section and Topic | Item | Checklist Item | Location Where Item Is Reported |
|---|---|---|---|
| TITLE | |||
| Title | 1 | Identify the report as a systematic review. | 1 |
| ABSTRACT | |||
| Abstract | 2 | See PRISMA 2020 for the Abstract checklist. | 1 |
| INTRODUCTION | |||
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | 1 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | 2 |
| METHODS | |||
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | 2 |
| Information sources | 6 | Specify all databases, registers, websites, organizations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | 2 |
| Search strategy | 7 | Present the full search strategies for all databases, registers, and websites, including any filters and limits used. | |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved; whether they worked independently; and if applicable, details of automation tools used in the process. | 2, 3 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report; whether they worked independently; any processes for obtaining or confirming data from study investigators; and if applicable, details of automation tools used in the process. | 2, 3 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | 2, 3 |
| 10b | List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | 2, 3 | |
| Study risk-of-bias assessment | 11 | Specify the methods used to assess the risk of bias in the included studies, including details of the tool(s) used; how many reviewers assessed each study and whether they worked independently; and if applicable, details of automation tools used in the process. | 2, 3 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results. | 2, 3 |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | 2, 3 |
| 13b | Describe any methods required to prepare the data for presentation; synthesis, such as handling of missing summary statistics; or conversions. | 2, 3 | |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | 2, 3 | |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | 2, 3 | |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression). | 2, 3 | |
| 13f | Describe any sensitivity analyses conducted to assess the robustness of the synthesized results. | 2, 3 | |
| Reporting bias assessment | 14 | Describe any methods used to assess the risk of bias due to missing results in a synthesis (arising from reporting biases). | 3 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | 3 |
| RESULTS | |||
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | 3 |
| 16b | Cite studies that might appear to meet the inclusion criteria but were excluded and explain why they were excluded. | 3 | |
| Study characteristics | 17 | Cite each included study and present its characteristics. | 4 |
| Risk of bias in studies | 18 | Present assessments of the risk of bias for each included study. | 4, |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots. | 4, |
| Results of syntheses | 20a | For each synthesis, briefly summarize the characteristics and the risk of bias among contributing studies. | 5, 6, 7, 8 |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | 5, 6, 7, 8 | |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | 5, 6, 7, 8 | |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | 8 | |
| Reporting biases | 21 | Present assessments of the risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | 8 |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. |
|
| DISCUSSION | |||
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | 8 |
| 23b | Discuss any limitations of the evidence included in the review. | 9 | |
| 23c | Discuss any limitations of the review processes used. | 9 | |
| 23d | Discuss implications of the results for practice, policy, and future research. | 9 | |
| OTHER INFORMATION | |||
| Registration and protocol | 24a | Provide registration information for the review, including the register name and the registration number, or state that the review was not registered. | 2 |
| 24b | Indicate where the review protocol can be accessed or state that a protocol was not prepared. | 2 | |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | 2 | |
| Support | 25 | Describe sources of financial or non-financial support for the review and the role of the funders or sponsors in the review. | 9 |
| Competing interests | 26 | Declare any competing interests of review authors. | 10 |
| Availability of data, code, and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms, data extracted from included studies, data used for all analyses, analytic code, and any other materials used in the review. | 24, 25, 26 |
Risk of Bias for Eligibility Studies for the Length of Hospital Stay.
| Authors | Risk of Bias 2 Tool Assessment | |||||
|---|---|---|---|---|---|---|
| Bias Arising from the Randomization Process | Bias Due to Deviations from Intended Interventions | Bias Due to Missing Outcome Data | Bias in the Measurement of the Outcome | Bias in the Selection of the Reported Results | Overall Risk of Bias | |
| Müller [ | Low | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Dulskas [ | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Piric [ | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Güngördük [ | Some concerns | Low | Low | Some concerns | High | High |
| Mohamed [ | Some concerns | High | High | Some concerns | Some concerns | High |
| Rabiepoor [ | Some concerns | Low | Low | Some concerns | Some concerns | Some concerns |
| Hasler-Gehrer [ | Low | Some concerns | Some concerns | Some concerns | High | High |
| Hayashi [ | Low | Low | Low | Some concerns | Low | High |
| Güngördük [ | Low | Some concerns | Some concerns | Some concerns | High | High |
| Parnasa [ | Low | Some concerns | Some concerns | Some concerns | Low | Some concerns |
Risk of Bias for the Eligibility Studies for Postoperative Ileus.
| Authors | Risk of Bias 2 Tool Assessment | |||||
|---|---|---|---|---|---|---|
| Bias Arising from the Randomization Process | Bias Due to Deviations from Intended Interventions | Bias Due to Missing Outcome Data | Bias in the Measurement of the Outcome | Bias in the Selection of the Reported Results | Overall Risk of Bias | |
| Müller [ | Low | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Dulskas [ | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Piric [ | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns | Some concerns |
| Güngördük [ | Some concerns | Low | Low | Some concerns | High | High |
| Mohamed [ | Some concerns | High | High | Some concerns | Some concerns | High |
| Hasler-Gehrer [ | Low | Some concerns | Some concerns | Some concerns | High | High |
| Bozkurt Koseoglu [ | Low | Some concerns | Some concerns | Some concerns | High | High |
| Güngördük [ | Low | Some concerns | Some concerns | Some concerns | High | High |
| Parnasa [ | Low | Some concerns | Some concerns | Some concerns | High | High |